PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-304.05%
Both yoy net incomes decline, with AGEN at -90.94%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
194.69%
Slight usage while AGEN is negative at -248.92%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
176.34%
AP growth well above AGEN's 38.26%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-34.25%
Both reduce yoy usage, with AGEN at -160.07%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
198.30%
Well above AGEN's 143.65%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
56.08%
Some CFO growth while AGEN is negative at -45.37%. John Neff would note a short-term liquidity lead over the competitor.
100.00%
CapEx growth well above AGEN's 43.27%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth well above AGEN's 100.00%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
100.00%
Investing outflow well above AGEN's 43.27%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
42.27%
We repay more while AGEN is negative at -58480.48%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.